Resmetirom · Rezdiffra

Small molecule

Also known as MGL-3196

Approvedregulatory verdict

Evidence outlook

Approved: MASH / NASH

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
UK
  • Adult patients with MASH with moderate (F2) to significant (F3) scarring; approved via the International Recognition Procedure
Product first approved 2026MHRA
EU
  • Conditional marketing authorisation: adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3), with diet and exercise
Product first approved 2025EMA

Company guidance: data expected in 2028 (NCT03900429; Madrigal Pharmaceuticals, 3 Nov 2026). “We expect outcomes data from MAESTRO-NASH in 2028.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
MASH / NASH
NCT04951219 · Madrigal Pharmaceuticals, Inc.
2021-07-09 – 2027-04 · Non-Alcoholic Fatty Liver Disease
What this study did
Phase 2 (5)
MASH / NASH
NCT07763015 · Madrigal Pharmaceuticals, Inc.
2026-08-01 – 2029-07 · MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
What this study did
NCT07335601 · Madrigal Pharmaceuticals, Inc.
2025-12-29 – 2029-03 · MASH - Metabolic Dysfunction-Associated Steatohepatitis
What this study did
NCT07143968 · Naga P. Chalasani
2026-04-23 – 2027-11 · MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
What this study did
NCT02912260 · Madrigal Pharmaceuticals, Inc.
2016-10-18 – 2021-11-23 · Non-alcoholic Steatohepatitis
What this study did
Other / comorbidity
NCT03038022 · Madrigal Pharmaceuticals, Inc.
2017-02-23 – 2018-01-15 · Heterozygous Familial Hypercholesterolemia
What this study did
Phase 1 (12)
MASH / NASH
NCT07830758 · Madrigal Pharmaceuticals, Inc.
2026-10-16 – 2027-12 · MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
What this study did
NCT04643795 · Madrigal Pharmaceuticals, Inc.
2018-10-25 – 2021-08-04 · Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
What this study did
Other / comorbidity
NCT07216313 · Sagimet Biosciences Inc.
2025-09-30 – 2025-10-20 · Healthy
What this study did
NCT04671069 · Madrigal Pharmaceuticals, Inc.
2019-07-26 – 2019-09-14 · Healthy
What this study did
NCT04671056 · Madrigal Pharmaceuticals, Inc.
2018-11-09 – 2019-01-05 · Healthy
What this study did
NCT03413124 · Madrigal Pharmaceuticals, Inc.
2018-02-05 – 2018-03-13 · Healthy
What this study did
NCT03220165 · Madrigal Pharmaceuticals, Inc.
2017-08-06 – 2017-09-03 · Healthy
What this study did
NCT02749578 · Madrigal Pharmaceuticals, Inc.
2016-04 – 2016-05 · Healthy
What this study did
NCT02542969 · Madrigal Pharmaceuticals, Inc.
2015-09 – 2015-10 · Healthy
What this study did
NCT01519531 · Madrigal Pharmaceuticals, Inc.
2012-01 – 2012-11 · Drug Safety
What this study did
NCT01367873 · Madrigal Pharmaceuticals, Inc.
2011-06 – 2011-10 · Drug Safety
What this study did
Phase 4 (2)
MASH / NASH
NCT07848191 · Madrigal Pharmaceuticals, Inc.
2026-10-07 – 2027-11 · MASH - Metabolic Dysfunction-Associated Steatohepatitis
What this study did
NCT07249788 · Nabiqasim Industries (Pvt) Ltd
2025-10-17 – 2026-12-31 · MASH - Metabolic Dysfunction-Associated Steatohepatitis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
MASH / NASH
NCT07680478 · City University of New York
2026-10-01 – 2028-06-30 · Metabolic Dysfunction-Associated Steatohepatitis (MASH)
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for MASH / NASH: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Resmetirom (Rezdiffra): this drugApprovedSmall moleculeThyroid hormone receptor-betaPartial signal
NCT03900429: Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1).
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ALN-CIDEBPhase 3RNA / oligonucleotideCIDEBnot yet gradedNo reviewed efficacy summary in this indication
AramcholPhase 3—Stearoyl-CoA desaturase 1 (SCD1)not yet gradedNo reviewed efficacy summary in this indication
Efimosfermin AlfaPhase 3Protein / enzyme therapeuticFGF21 receptorWeak signalFeatured results are safety only in this race
LanifibranorPhase 3Small moleculePeroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist)Partial signalNo reviewed efficacy summary in this indication
PegozaferminPhase 3Protein / enzyme therapeuticFGFR1c/2c/3c–β-Klotho agonistnot yet gradedNo reviewed efficacy summary in this indication
PemvidutidePhase 3PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT05989711: Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26).
SurvodutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT06309992: Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met.
BelapectinPhase 2/3PolysaccharideGalectin-3Partial signal
NCT04365868: Proportion of patients with new esophageal varices at 78 weeks (registry): belapectin 2 mg/kg 45/119, belapectin 4 mg/kg 51/118 vs placebo 56/118. The sponsor reports that the composite primary endpoint did not reach statistical significance in the intent-to-treat population (n=355); in the pre-defined per-protocol population (n=290), the 2 mg/kg group showed a 48.9% reduction in varices (p<0.05). missed
NCT02421094: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) (16 weeks): GR-MD-02 8 mg/kg 19.15 milliseconds (ms) (95% CI -7.7 to 43.5) vs Placebo 1.25 milliseconds (ms) (95% CI -7.7 to 43.5) missed
ALG-055009Phase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
ALN-PNPPhase 2RNA / oligonucleotidePNPLA3Weak signalNo reviewed efficacy summary in this indication
DenifanstatPhase 2Small moleculeFatty acid synthase (FASN), FASNReliable signal
NCT04906421: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score). (52 Weeks): ITT: TVB-2640 50 mg 42/112 | mITT: TVB-2640 50 mg 42/81 vs ITT: Placebo 9/56 | mITT: Placebo 9/45
NCT03938246: Relative change in liver fat (MRI-PDFF) at week 12 vs placebo (+4.5%): -9.6% with 25 mg (LS mean difference -15.5%; 95% CI -31.3 to -0.23; P=.053) and -28.1% with 50 mg (LS mean difference -28.0%; 95% CI -44.5 to -11.6; P=.001) (FASCINATE-1, Gastroenterology 2021).
ECC4703Phase 2—Thyroid hormone receptor beta (THRβ)not yet gradedNo reviewed efficacy summary in this indication
EfinopegdutidePhase 2PeptideGLP-1/glucagon receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
EfocipegtrutidePhase 2PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
Elunetirom
Phase 2(overall)
Small moleculeThyroid hormone receptor-beta
not yet graded(overall)
No reviewed efficacy summary in this indication
ErvogastatPhase 2Small moleculeDiacylglycerol acyltransferase 2 (DGAT2)Partial signal
NCT04321031: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) (Week 48): DGAT2i/PF-06865571 25 mg BID 45% (95% CI 38% to 53%) | DGAT2i/PF-06865571 75 mg BID 48% (95% CI 42% to 55%) | DGAT2i/PF-06865571 150 mg BID 50% (95% CI 43% to 57%) | DGAT2i/PF-06865571 300 mg BID 51% (95% CI 43% to 59%) vs Placebo 38% (95% CI 26% to 50%)
NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89)
GatuzosiranPhase 2RNA / oligonucleotideHSD17B13Weak signal
NCT06104319: Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg)
NCT04202354: Treatment-related TEAEs: 0/4 with ARO-HSD 25 mg, 0/4 with 50 mg, 1/4 with 100 mg, and 3/4 with 200 mg versus 0/16 with pooled placebo.
HU6Phase 2Small moleculeMitochondrial uncouplingnot yet gradedNo reviewed efficacy summary in this indication
MiricorilantPhase 2Small moleculeGlucocorticoid receptorWeak signal
NCT05117489: Open-label study in patients with presumed non-alcoholic steatohepatitis: patients who received 100 mg of miricorilant orally every Monday and Friday for 12 weeks experienced an approximately 30 percent reduction in liver fat as assessed by MRI-PDFF and showed improvements in liver enzymes and markers of liver disease.
NamodenosonPhase 2—Adenosine A3 receptorPartial signal
NCT02927314: Change from baseline in serum ALT at Week 12, namodenoson 25 mg b.d. vs placebo: P=0.066 (trend, not statistically significant) missed
ORMD-0801Phase 2PeptideInsulinnot yet gradedNo reviewed efficacy summary in this indication
Rapirosiran (ALN-HSD)Phase 2RNA / oligonucleotideHSD17B13Weak signalFeatured results are safety only in this race
TipelukastPhase 2Small moleculeCysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenasenot yet gradedNo reviewed efficacy summary in this indication
VanoglipelPhase 2Small moleculeGPR119not yet gradedNo reviewed efficacy summary in this indication
VK2809Phase 2Small moleculeThyroid hormone receptor-betaPartial signal
NCT04173065: Primary: liver fat reduction (MRI-PDFF) at Week 12, mean relative change -45.3% (2.5 mg QD), -36.8% (5 mg QOD), -51.7% (10 mg QOD), each p<0.0001 vs placebo. Secondary, 52-week biopsy: NASH resolution with no worsening of fibrosis 63% to 75% vs 29% placebo (p<0.05 each arm); >=1-stage fibrosis improvement with no worsening of NASH 44% to 57% vs 34% placebo (p<0.05 for the 5 mg and 10 mg QOD arms only).
NCT02927184: Primary endpoint, placebo-adjusted % change in LDL-C at week 12: VK2809 10mg every-other-day -23.6% (p=0.0121); VK2809 10mg daily -20.2% (p=0.0269); combined VK2809 -21.8% (p=0.0061).
VonafexorPhase 2Small moleculeFarnesoid X receptor (FXR/NR1H4)Partial signal
NCT03812029: Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) (12 weeks): Vonafexor 100 mg QD Part B -6.3% (95% CI -8.1 to -4.5) | Vonafexor 200 mg QD Part B -5.4% (95% CI -7.2 to -3.6) vs Placebo Part B -2.3% (95% CI -4 to -0.6) | Placebo Part A 3.9% (95% CI -2.5 to 10.4)
ZabopegdutidePhase 2PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT06410924: Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001.
OPK-88006Phase 1/2—GLP-1/glucagon receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ARO-PNPLA3
Phase 1(overall)
RNA / oligonucleotidePNPLA3not yet gradedNo reviewed efficacy summary in this indication
ASC47
Phase 1(overall)
Small moleculeThyroid hormone receptor-beta
Partial signal(overall)
No reviewed efficacy summary in this indication
AZD2389
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BI 3006337Phase 1——Weak signalFeatured results are safety only in this race
BI 3804379Phase 1——not yet gradedNo reviewed efficacy summary in this indication
ZT003
Phase 1(overall)
PeptideFGF21/GLP-1 receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
NNC4005-001
—(overall)
RNA / oligonucleotideSLC25A5not yet gradedNo reviewed efficacy summary in this indication
AZD7503DiscontinuedRNA / oligonucleotideHSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) mRNAWeak signalNo reviewed efficacy summary in this indication
ClesacostatDiscontinuedSmall moleculeAcetyl-CoA carboxylase (ACC1/ACC2)Partial signal
NCT04321031: Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model (Week 48): DGAT2i/PF-06865571 150 mg BID + ACCi/PF-05221304 5 mg BID 23/35 | DGAT2i/PF-06865571 300 mg BID + ACCi/PF-05221304 10 mg BID 19/30 vs Placebo 13/34 | DGAT2i/PF-06865571 25 mg BID 16/35 | DGAT2i/PF-06865571 75 mg BID 25/48 | DGAT2i/PF-06865571 150 mg BID 21/42 | DGAT2i/PF-06865571 300 mg BID 14/31
NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89)
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication
PF-05221304 + PF-06865571DiscontinuedSmall moleculeAcetyl-CoA carboxylase (ACC1/ACC2) + Diacylglycerol acyltransferase 2Partial signal
NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89)
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rezdiffra (Resmetirom) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2026-12 · NCT05500222 · CT.gov ↗
What to watch
2027 (4)
March 2027 (1)
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2027-03 · NCT04951219 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2MASH / NASHRecruiting
Est. primary completion 2027-10 · NCT07143968 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1MASH / NASHRecruiting
Est. primary completion 2027-11 · NCT07830758 · CT.gov ↗
What to watch
Phase 4MASH / NASHRecruiting
Est. primary completion 2027-11 · NCT07848191 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2028-01 · NCT03900429 · CT.gov ↗

Company guidance: data expected in 2028 (Madrigal Pharmaceuticals, 3 Nov 2026). “We expect outcomes data from MAESTRO-NASH in 2028.” Source ↗

What to watch
August 2028 (1)
Phase 2MASH / NASHRecruiting
Est. primary completion 2028-08 · NCT07335601 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 2MASH / NASHRecruiting
Est. primary completion 2029-07 · NCT07763015 · CT.gov ↗
What to watch

See the full readout calendar ↗